← All trials
NCT04918927
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 12, 2021
- Primary completion
- Jan 31, 2022
- Completion date
- Mar 31, 2022
- First posted
- Jun 9, 2021
- Last posted
- Oct 19, 2021
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Government of MexicoLead sponsor
- SiegfriedCollaborator
- University of LondonCollaborator
- Government of MexicoReponsible party - principal investigator
- Instituto Mexicano del Seguro SocialOverall official - principal investigator
- National Polytechnic Institute, MexicoCollaborator
- Universidad Autonoma De Guadalajara, MexicoCollaborator
- Hakken EnterpriseCollaborator
- Strides Pharma ScienceCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.